Evidence map›Paper›PMID 40351069›Full record

ArticleMedicinal chemistry (Shariqah (United Arab Emirates))2025

Synthesis, Characterization, and

Zeynep Livanur Uzmez, Derya Osmaniye, Yusuf Ozkay, Zafer Asım Kaplancıklı

Abstract read
In one paragraph

Article in Medicinal chemistry (Shariqah (United Arab Emirates)), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zeynep Livanur UzmezFaculty of Pharmacy, Anadolu University, Eskişehir 26470, Turkey.
Derya OsmaniyeDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir 26470, Turkey.
Yusuf OzkayDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir 26470, Turkey.
Zafer Asım KaplancıklıDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir 26470, Turkey.

Funding

Research Fund of Tubitak 2209-A project 1919B012201803
6 · The paper itself

Abstract

introductionBreast cancer is the most common type of cancer among women. Steroidal or non-steroidal aromatase inhibitors (NSAIs) are used clinically, and in most cancer diseases, resistance is the most important problem.

methodsThe nitrogenous heterocyclic ring is noteworthy in the structure of non-steroidal aromatase inhibitors. This is the pharmacophore structure for aromatase inhibition. Because the enzyme interacts with the Fe

resultsThe synthesis was carried out by a 4-step reaction. The anticancer effects of the compounds were evaluated by MTT assay performed on A549 and MCF-7 cancer cells. Compound 4d showed anticancer activity against the MCF-7 cell line with IC

conclusionThe interactions observed as a result of molecular docking and dynamics studies are in harmony with activity studies. In particular, interactions with HEM600 demonstrate the activity potential of the compound.

Indexed as

Antineoplastic AgentsAromatase InhibitorsTriazolesA549 CellsAromataseCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMCF-7 CellsMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsAromataseAromatase InhibitorsTriazolesaromatase inhibitorBreast cancerestrogen.molecular dockingmolecular dynamicstriazole

Identifiers

PMID40351069
PMCPMC12606616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.